Oncolytics Biotech Inc. (TSX:ONC)
Canada · Delayed Price · Currency is CAD 1.420
+0.030 (2.16%)
Inactive · Last trade price on Aug 22, 2025
Oncolytics Biotech Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jared Kelly |
Contact Details
Address: 322 11th Avenue SW Calgary, Alberta T2R 0C5 Canada | |
| Phone | 403-670-7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONC |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jared Kelly J.D., L.L.M. | Chief Executive Officer and Director |
| Kirk J. Look C.A., CPA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations |
| Jon Patton | Director of Investor Relations and Communication |
| Andrew P. Aromando | Chief Business Officer |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |